Audit Information	12 Months Ended
Dec. 31, 2025
Auditor [Line Items]
Auditor Name	GRANT THORNTON LLP
Auditor Firm ID	248
Auditor Location	Edison, New Jersey
Auditor Opinion [Text Block]	Opinion on the financial statements We have audited the accompanying balance sheets of Polaryx Therapeutics, Inc. (a Nevada corporation) (the “Company”) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

248

Opinion on the financial statements

We have audited the accompanying balance sheets of Polaryx Therapeutics, Inc. (a Nevada corporation) (the “Company”) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.